| 纯度 | >85%SDS-PAGE. |
| 种属 | Human |
| 靶点 | APOA2 |
| Uniprot No | P02652 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 24-100aa |
| 氨基酸序列 | QAKEPCVESLVSQYFQTVTDYGKDLMEKVKSPELQAEAKSYFEKSKEQLTPLIKKAGTELVNFLSYFVELGTQPATQ |
| 预测分子量 | 21.7 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于APOA2重组蛋白的3篇模拟参考文献示例，基于典型研究方向构建：
---
1. **文献名称**: "Expression and Purification of Recombinant Human Apolipoprotein A-II in Escherichia coli"
**作者**: Chen et al.
**摘要**: 本研究成功在大肠杆菌中表达并纯化重组人源APOA2蛋白，优化了表达条件以提高产量，并通过质谱和圆二色谱验证了其结构与天然蛋白的一致性，为功能研究奠定基础。
2. **文献名称**: "Recombinant APOA2 Modulates HDL Metabolism and Cholesterol Efflux in Macrophages"
**作者**: Johnson et al.
**摘要**: 利用重组APOA2蛋白的体外实验表明，其能够增强HDL介导的巨噬细胞胆固醇外流，并调节关键脂代谢酶活性，提示APOA2在抗动脉粥样硬化中的潜在作用。
3. **文献名称**: "Crystal Structure of Recombinant APOA2 Reveals Lipid-Binding Mechanisms"
**作者**: Wang et al.
**摘要**: 通过X射线晶体学解析重组APOA2的三维结构，发现其特定结构域与脂质结合的分子机制，为理解APOA2在HDL组装中的功能提供结构生物学依据。
---
以上示例涵盖重组蛋白的制备、功能机制及结构解析等方向，符合常见研究主题。实际文献需通过学术数据库检索获取。
Apolipoprotein A-II (APOA2) is a key component of high-density lipoprotein (HDL), playing a critical role in lipid metabolism and cardiovascular health. As the second most abundant protein in HDL, it influences HDL structure, stability, and function, particularly in cholesterol transport and reverse cholesterol transport (RCT). APOA2 is synthesized primarily in the liver and exists as a homodimer or heterodimer, interacting with other apolipoproteins like APOA1 to modulate HDL’s metabolic fate. Genetic variations in APOA2 have been linked to dyslipidemia, obesity, and atherosclerosis, highlighting its clinical relevance.
Recombinant APOA2 protein is produced using biotechnological systems (e.g., E. coli, yeast, or mammalian cells) to enable controlled study of its biochemical and physiological roles. Its recombinant form allows researchers to investigate molecular mechanisms underlying HDL metabolism, including ligand binding, enzyme regulation (e.g., hepatic lipase), and receptor interactions. Studies using recombinant APOA2 have clarified its dual role: while it stabilizes HDL particles, excessive APOA2 may reduce HDL’s cardioprotective efficiency by altering particle size or function.
Beyond basic research, recombinant APOA2 has therapeutic potential. It serves as a tool for developing HDL-targeted therapies to address cardiovascular diseases (CVDs) or metabolic syndromes. For instance, synthetic HDL formulations incorporating recombinant APOA2 are explored for enhancing RCT or reducing inflammation. Additionally, it aids in diagnostic assay development to measure APOA2 levels, which may correlate with disease risk.
Challenges remain in optimizing recombinant APOA2’s functional fidelity, as post-translational modifications (e.g., glycosylation) in native HDL may differ from lab-produced versions. Advances in expression systems and protein engineering aim to address these limitations, paving the way for translational applications in precision medicine and personalized CVD management.
×
